Byoung Chul Cho
#136,745
Most Influential Person Now
Researcher
Byoung Chul Cho's AcademicInfluence.com Rankings
Byoung Chul Chocomputer-science Degrees
Computer Science
#6311
World Rank
#6657
Historical Rank
Machine Learning
#2003
World Rank
#2029
Historical Rank
Artificial Intelligence
#2254
World Rank
#2292
Historical Rank
Database
#3408
World Rank
#3550
Historical Rank
Download Badge
Computer Science
Byoung Chul Cho's Degrees
- PhD Computer Science Stanford University
- Masters Computer Science Stanford University
Similar Degrees You Can Earn
Why Is Byoung Chul Cho Influential?
(Suggest an Edit or Addition)Byoung Chul Cho's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Osimertinib in Untreated EGFR‐Mutated Advanced Non–Small‐Cell Lung Cancer (2018) (2753)
- Durvalumab after Chemoradiotherapy in Stage III Non–Small‐Cell Lung Cancer (2017) (1959)
- Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial (2019) (1742)
- Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC (2018) (1690)
- Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC. (2019) (1165)
- Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M (2015) (926)
- Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. (2019) (540)
- CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. (2018) (406)
- Mechanisms of acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (2018) (354)
- Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non–Small Cell Lung Cancer (2020) (323)
- Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. (2016) (322)
- Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study (2021) (299)
- Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer. (2020) (297)
- Dabrafenib in patients with BRAF(V600E)-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial. (2016) (297)
- Tepotinib in Non‐Small Cell Lung Cancer with MET Exon 14‐Skipping Mutations or MET Amplification: a Phase 2 Trial in Progress: OA06 (2018) (294)
- Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. (2018) (282)
- Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non-Small Cell Lung Cancer in the Global Phase III ALEX Study. (2019) (281)
- Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC (2019) (275)
- Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (2018) (265)
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. (2018) (248)
- Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. (2019) (241)
- Open-Label, Multicenter, Phase II Study of Ceritinib in Patients With Non-Small-Cell Lung Cancer Harboring ROS1 Rearrangement. (2017) (235)
- Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial. (2020) (232)
- Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study. (2020) (211)
- Nivolumab in NSCLC: latest evidence and clinical potential (2015) (201)
- Acquired resistance to EGFR targeted therapy in non-small cell lung cancer: Mechanisms and therapeutic strategies. (2018) (179)
- PD-L1 expression on immune cells, but not on tumor cells, is a favorable prognostic factor for head and neck cancer patients (2016) (178)
- Activation of IL-6R/JAK1/STAT3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non–Small Cell Lung Cancer with T790M Resistance Mutation (2012) (175)
- Pembrolizumab (pembro) versus platinum-based chemotherapy (chemo) as first-line therapy for advanced/metastatic NSCLC with a PD-L1 tumor proportion score (TPS) ≥ 1%: Open-label, phase 3 KEYNOTE-042 study. (2018) (174)
- Amivantamab in EGFR Exon 20 Insertion–Mutated Non–Small-Cell Lung Cancer Progressing on Platinum Chemotherapy: Initial Results From the CHRYSALIS Phase I Study (2021) (168)
- Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib (2008) (166)
- Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study (2019) (162)
- Primary analysis of a randomized, double-blind, phase II study of the anti-TIGIT antibody tiragolumab (tira) plus atezolizumab (atezo) versus placebo plus atezo as first-line (1L) treatment in patients with PD-L1-selected NSCLC (CITYSCAPE). (2020) (155)
- Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer. (2013) (153)
- Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer (2022) (150)
- Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib. (2007) (144)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (142)
- Activation of Transforming Growth Factor Beta 1 Signaling in Gastric Cancer-associated Fibroblasts Increases Their Motility, via Expression of Rhomboid 5 Homolog 2, and Ability to Induce Invasiveness of Gastric Cancer Cells. (2017) (139)
- ASCEND‐8: A Randomized Phase 1 Study of Ceritinib, 450 mg or 600 mg, Taken with a Low‐Fat Meal versus 750 mg in Fasted State in Patients with Anaplastic Lymphoma Kinase (ALK)‐Rearranged Metastatic Non–Small Cell Lung Cancer (NSCLC) (2017) (139)
- Enhanced Antitumor Effect of Oncolytic Adenovirus Expressing Interleukin-12 and B7-1 in an Immunocompetent Murine Model (2006) (132)
- Distinct clinical features and outcomes in never‐smokers with nonsmall cell lung cancer who harbor EGFR or KRAS mutations or ALK rearrangement (2012) (131)
- Long-Term Outcomes and Retreatment Among Patients With Previously Treated, Programmed Death-Ligand 1‒Positive, Advanced Non‒Small-Cell Lung Cancer in the KEYNOTE-010 Study. (2020) (130)
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. (2019) (128)
- LBA8_PR Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study (2020) (126)
- Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. (2018) (124)
- Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study. (2021) (118)
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS (2019) (117)
- A multicenter, phase II trial of everolimus in locally advanced or metastatic thyroid cancer of all histologic subtypes. (2013) (115)
- Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status. (2016) (114)
- Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial. (2014) (113)
- The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. (2013) (110)
- KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer. (2019) (110)
- Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall‐cell lung cancer (2010) (109)
- Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study. (2019) (107)
- Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial. (2020) (105)
- A single-tube multiplexed assay for detecting ALK, ROS1, and RET fusions in lung cancer. (2014) (103)
- Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor -mutant non-small cell lung cancer. (2016) (103)
- Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-cMet Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. (2020) (101)
- Osimertinib activity in patients (pts) with leptomeningeal (LM) disease from non-small cell lung cancer (NSCLC): Updated results from BLOOM, a phase I study. (2016) (100)
- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer (2014) (96)
- Prognostic impact of resection margin involvement after extended (D2/D3) gastrectomy for advanced gastric cancer: A 15‐year experience at a single institute (2007) (90)
- Osimertinib for patients (pts) with leptomeningeal metastases (LM) from EGFR-mutant non-small cell lung cancer (NSCLC): Updated results from the BLOOM study. (2017) (87)
- Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study. (2019) (84)
- A Phase I/Ib Trial of the VEGFR-Sparing Multikinase RET Inhibitor RXDX-105. (2018) (83)
- Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study. (2017) (82)
- High Tumor Metabolic Activity as Measured by Fluorodeoxyglucose Positron Emission Tomography Is Associated with Poor Prognosis in Limited and Extensive Stage Small-Cell Lung Cancer (2009) (82)
- Ethnic Differences in Survival Outcome in Patients with Advanced Stage Non-small Cell Lung Cancer: Results of a Meta-Analysis of Randomized Controlled Trials (2011) (79)
- Lung cancer in never smokers: change of a mindset in the molecular era. (2011) (79)
- Osimertinib versus Standard of Care EGFR TKI as First‐Line Treatment in Patients with EGFRm Advanced NSCLC: FLAURA Asian Subset (2019) (78)
- Screening of ROS1 Rearrangements in Lung Adenocarcinoma by Immunohistochemistry and Comparison with ALK Rearrangements (2014) (78)
- Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea. (2015) (78)
- Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance (2015) (77)
- A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy. (2020) (75)
- Impact of environmental tobacco smoke on the incidence of mutations in epidermal growth factor receptor gene in never-smoker patients with non-small-cell lung cancer. (2010) (75)
- Glycolysis Inhibition Sensitizes Non–Small Cell Lung Cancer with T790M Mutation to Irreversible EGFR Inhibitors via Translational Suppression of Mcl-1 by AMPK Activation (2013) (75)
- ENCORE: Updated efficacy and safety data from the global phase III ALEX study of alectinib (ALC) vs. crizotinib (CZ) in untreated advanced ALK+ NSCLC (2018) (74)
- Tumor-infiltrating regulatory T cells delineated by upregulation of PD-1 and inhibitory receptors. (2012) (73)
- Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma (2009) (73)
- PL02.08 Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of LOXO-292 in Patients with RET Fusion-Positive Lung Cancers (2019) (71)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in second-line treatment of patients with non-small cell lung cancer: results from an expansion cohort of a phase 1 trial. (2020) (71)
- Abstract CT074: Tumor mutational burden (TMB) as a biomarker of survival in metastatic non-small cell lung cancer (mNSCLC): Blood and tissue TMB analysis from MYSTIC, a Phase III study of first-line durvalumab ± tremelimumab vs chemotherapy. (2019) (71)
- Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition (2017) (69)
- Efficacy and safety of dovitinib in pretreated patients with advanced squamous non‐small cell lung cancer with FGFR1 amplification: A single‐arm, phase 2 study (2016) (68)
- Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. (2019) (68)
- Immunotherapy in the treatment of non-small cell lung cancer. (2014) (67)
- Safety and preliminary clinical activity of repotrectinib in patients with advanced ROS1 fusion-positive non-small cell lung cancer (TRIDENT-1 study). (2019) (67)
- Characteristics and Outcome of ROS1‐Positive Non–Small Cell Lung Cancer Patients in Routine Clinical Practice (2018) (67)
- Consensus recommendations for management of head and neck cancer in Asian countries: a review of international guidelines. (2013) (67)
- Impact of Tumor Purity on Immune Gene Expression and Clustering Analyses across Multiple Cancer Types (2017) (66)
- Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study. (2019) (65)
- Congenital absence of inferior vena cava as a rare cause of pulmonary thromboembolism. (2004) (65)
- LBA4 Association of KRAS mutational status with response to pembrolizumab monotherapy given as first-line therapy for PD-L1-positive advanced non-squamous NSCLC in Keynote-042 (2019) (65)
- Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers (2014) (64)
- The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti-PD-1 Therapy in Patients with Non-Small Cell Lung Cancer. (2019) (64)
- Acquired resistance to cetuximab is mediated by increased PTEN instability and leads cross-resistance to gefitinib in HCC827 NSCLC cells. (2010) (64)
- 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death Ligand 1-Positive Advanced Non-Small-Cell Lung Cancer. (2021) (62)
- High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma (2012) (62)
- A Case of ALK-Rearranged Adenocarcinoma with Small Cell Carcinoma-Like Transformation and Resistance to Crizotinib. (2016) (60)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies (2020) (60)
- Preoperative C-reactive protein levels are associated with tumor size and lymphovascular invasion in resected non-small cell lung cancer. (2009) (60)
- Phase II Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of Head and Neck (2014) (58)
- Clinical and prognostic implications of ALK and ROS1 rearrangements in never-smokers with surgically resected lung adenocarcinoma. (2014) (58)
- JNJ-61186372 (JNJ-372), an EGFR-cMet bispecific antibody, in EGFR-driven advanced non-small cell lung cancer (NSCLC). (2019) (58)
- Impact of Treatment-Related Lymphopenia on Immunotherapy for Advanced Non-Small Cell Lung Cancer. (2019) (58)
- Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center Experience (2012) (58)
- Phase 2 study of dovitinib in patients with metastatic or unresectable adenoid cystic carcinoma (2015) (57)
- Genome-wide identification of differentially methylated promoters and enhancers associated with response to anti-PD-1 therapy in non-small cell lung cancer (2020) (56)
- Impact of cigarette smoking on response to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors in lung adenocarcinoma with activating EGFR mutations. (2014) (56)
- Registrational dataset from the phase I/II ARROW trial of pralsetinib (BLU-667) in patients (pts) with advanced RET fusion+ non-small cell lung cancer (NSCLC). (2020) (55)
- Tiragolumab plus atezolizumab versus placebo plus atezolizumab as a first-line treatment for PD-L1-selected non-small-cell lung cancer (CITYSCAPE): primary and follow-up analyses of a randomised, double-blind, phase 2 study. (2022) (55)
- Personalized therapy on the horizon for squamous cell carcinoma of the lung. (2013) (54)
- Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer (2011) (54)
- Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non–small‐cell Lung Cancer (2019) (53)
- Comprehensive analysis of the characteristics and treatment outcomes of patients with non-small cell lung cancer treated with anti-PD-1 therapy in real-world practice (2019) (53)
- Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus (2016) (52)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared with Topotecan as Second-Line Therapy in DLL3-High Small Cell Lung Cancer: Results from the Phase 3 TAHOE Study. (2021) (51)
- Amivantamab (JNJ-61186372), an anti-EGFR-MET bispecific antibody, in patients with EGFR exon 20 insertion (exon20ins)-mutated non-small cell lung cancer (NSCLC). (2020) (51)
- 1173OMAGRIT, A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF THE RECMAGE-A3 + AS15 CANCER IMMUNOTHERAPEUTIC AS ADJUVANT THERAPY IN PATIENTS WITH RESECTED MAGE-A3-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC). (2014) (49)
- Oral MEK1/MEK2 inhibitor trametinib (GSK1120212) in combination with docetaxel in KRAS-mutant and wild-type (WT) advanced non-small cell lung cancer (NSCLC): A phase I/Ib trial. (2013) (49)
- Activation of the Met kinase confers acquired drug resistance in FGFR-targeted lung cancer therapy (2016) (47)
- Next-generation sequencing reveals novel resistance mechanisms and molecular heterogeneity in EGFR-mutant non-small cell lung cancer with acquired resistance to EGFR-TKIs. (2017) (47)
- Differences in outcome and toxicity between Asian and caucasian patients with lung cancer treated with systemic therapy. (2012) (46)
- Efficacy and Safety of Ceritinib (450 mg/d or 600 mg/d) With Food Versus 750-mg/d Fasted in Patients With ALK Receptor Tyrosine Kinase (ALK)-Positive NSCLC: Primary Efficacy Results From the ASCEND-8 Study. (2019) (46)
- Safety, tolerability, and anti-tumor activity of olmutinib in non-small cell lung cancer with T790M mutation: A single arm, open label, phase 1/2 trial. (2019) (46)
- Repotrectinib Exhibits Potent Antitumor Activity in Treatment-Naïve and Solvent-Front–Mutant ROS1-Rearranged Non–Small Cell Lung Cancer (2020) (45)
- YH25448, an Irreversible EGFR-TKI with Potent Intracranial Activity in EGFR Mutant Non–Small Cell Lung Cancer (2019) (44)
- BI 1482694 (HM61713), an EGFR mutant-specific inhibitor, in T790M+ NSCLC: Efficacy and safety at the RP2D. (2016) (44)
- Targeted sequencing identifies genetic alterations that confer primary resistance to EGFR tyrosine kinase inhibitor (Korean Lung Cancer Consortium) (2016) (44)
- Updated survival of patients (pts) with previously treated BRAF V600E–mutant advanced non-small cell lung cancer (NSCLC) who received dabrafenib (D) or D + trametinib (T) in the phase II BRF113928 study. (2017) (44)
- Prediction for response duration to epidermal growth factor receptor-tyrosine kinase inhibitors in EGFR mutated never smoker lung adenocarcinoma. (2014) (42)
- Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response. (2021) (42)
- Significance of immune checkpoint proteins in EGFR-mutant non-small cell lung cancer. (2017) (42)
- Cancer in Patients on Chronic Dialysis in Korea (2009) (42)
- Clinical and echocardiographic characteristics of pericardial effusion in patients who underwent echocardiographically guided pericardiocentesis: Yonsei Cardiovascular Center experience, 1993-2003. (2004) (41)
- Tumor microenvironment dictates regulatory T cell phenotype: Upregulated immune checkpoints reinforce suppressive function (2019) (40)
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion–Positive Non–Small-Cell Lung Cancer (2021) (40)
- Genomic profiling of lung adenocarcinoma patients reveals therapeutic targets and confers clinical benefit when standard molecular testing is negative (2016) (40)
- An open label, multicenter, phase II study of dovitinib in advanced thyroid cancer. (2015) (39)
- ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positive non-small-cell lung cancer. (2019) (39)
- Intracranial Efficacy of Selpercatinib in RET Fusion-Positive Non–Small Cell Lung Cancers on the LIBRETTO-001 Trial (2021) (39)
- Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors (2013) (39)
- Prognostic and predictive value of CEA and CYFRA 21-1 levels in advanced non-small cell lung cancer patients treated with gefitinib or erlotinib. (2011) (37)
- Thoracoscopic lobectomy is associated with superior compliance with adjuvant chemotherapy in lung cancer. (2011) (37)
- The prognostic factors of resected non-small cell lung cancer with chest wall invasion (2012) (37)
- PL02.01 Durvalumab ± Tremelimumab + Chemotherapy as First-line Treatment for mNSCLC: Results from the Phase 3 POSEIDON Study (2021) (36)
- Treatment options for EGFR mutant NSCLC with CNS involvement-Can patients BLOOM with the use of next generation EGFR TKIs? (2017) (35)
- Clinical course of stage IV invasive mucinous adenocarcinoma of the lung. (2016) (35)
- Early clearance of plasma EGFR mutations as a predictor of response to osimertinib and comparator EGFR-TKIs in the FLAURA trial. (2019) (34)
- Final analysis of the phase III KEYNOTE-042 study: Pembrolizumab (Pembro) versus platinum-based chemotherapy (Chemo) as first-line therapy for patients (Pts) with PD-L1-positive locally advanced/metastatic NSCLC. (2019) (34)
- KEYNOTE-975 study design: a Phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma (2021) (33)
- Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort (2020) (33)
- Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer. (2020) (32)
- A phase II trial of S-1 monotherapy in metastatic colorectal cancer after failure of irinotecan- and oxaliplatin-containing regimens (2006) (32)
- Design and Rationale for a Phase III, Randomized, Placebo-controlled Trial of Durvalumab With or Without Tremelimumab After Concurrent Chemoradiotherapy for Patients With Limited-stage Small-cell Lung Cancer: The ADRIATIC Study. (2019) (31)
- Patient-reported outcomes from FLAURA: Osimertinib versus erlotinib or gefitinib in patients with EGFR-mutated advanced non-small-cell lung cancer. (2019) (31)
- PF-00299804 (PF299) in Asian patients (pts) with non-small cell lung cancer (NSCLC) refractory to chemotherapy (CT) and erlotinib (E) or gefitinib (G): A phase (P) I/II study. (2010) (30)
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (30)
- A single institutional experience of surgically resected thymic epithelial tumors over 10 years: clinical outcomes and clinicopathologic features. (2008) (30)
- Targeting YAP to overcome acquired resistance to ALK inhibitors in ALK‐rearranged lung cancer (2019) (29)
- Rovalpituzumab Tesirine as a Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer: Results From the Phase 3 MERU Study. (2021) (29)
- Efficacy and Safety of Rovalpituzumab Tesirine Compared With Topotecan as Second-Line Therapy in DLL3-High SCLC: Results From the Phase 3 TAHOE Study (2021) (28)
- Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma (2014) (28)
- Abstract CT084: Relationship betweenSTK11andKEAP1mutational status and efficacy in KEYNOTE-042: pembrolizumab monotherapy versus platinum-based chemotherapy as first-line therapy for PD-L1-positive advanced NSCLC (2020) (28)
- Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer (2020) (28)
- A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC). (2019) (28)
- 1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC (2020) (27)
- A randomized phase 2 trial of MM-121, a fully human monoclonal antibody targeting ErbB3, in combination with erlotinib in EGFR wild-type NSCLC patients. (2014) (27)
- ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma (2018) (27)
- First-line systemic treatment of advanced stage non-small-cell lung cancer in Asia: consensus statement from the Asian Oncology Summit 2009. (2009) (27)
- LBA38_PRDABRAFENIB IN PATIENTS WITH BRAF V600E-MUTANT ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC): A MULTICENTER, OPEN-LABEL, PHASE II TRIAL (BRF113928) (2014) (27)
- A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen (2005) (27)
- Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors (2022) (26)
- Cabazitaxel Versus Topotecan in Patients with Small-Cell Lung Cancer with Progressive Disease During or After First-Line Platinum-Based Chemotherapy (2015) (26)
- Modeling Clinical Responses to Targeted Therapies by Patient-Derived Organoids of Advanced Lung Adenocarcinoma (2021) (26)
- 1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC (2020) (26)
- Abstract CT032: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior first/second-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) (2019) (25)
- Randomized Phase II Trial of Seribantumab in Combination with Erlotinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer. (2019) (25)
- Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (2009) (25)
- EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI (2012) (25)
- Enhancer Remodeling and MicroRNA Alterations Are Associated with Acquired Resistance to ALK Inhibitors. (2018) (25)
- Dose effect of cigarette smoking on frequency and spectrum of epidermal growth factor receptor gene mutations in Korean patients with non-small cell lung cancer (2010) (25)
- Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. (2020) (25)
- Investigating the Feasibility of Targeted Next-Generation Sequencing to Guide the Treatment of Head and Neck Squamous Cell Carcinoma (2018) (25)
- OA03.07 KEYNOTE-010: Durable Clinical Benefit in Patients with Previously Treated, PD-L1-Expressing NSCLC Who Completed Pembrolizumab (2017) (24)
- Preclinical Development Activation of IL-6 R / JAK 1 / STAT 3 Signaling Induces De Novo Resistance to Irreversible EGFR Inhibitors in Non – Small Cell Lung Cancer with T 790 M Resistance Mutation (2012) (24)
- Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models. (2019) (24)
- A prospective phase II trial of S-1 and cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer (2014) (24)
- MARIPOSA: phase 3 study of first-line amivantamab + lazertinib versus osimertinib in EGFR-mutant non-small cell lung cancer. (2021) (24)
- Efficacy and safety of entrectinib in patients (pts) with NTRK-fusion positive (NTRK-fp) solid tumors: An updated integrated analysis. (2020) (23)
- OA04.04 Amivantamab in Post-platinum EGFR Exon 20 Insertion Mutant Non-small Cell Lung Cancer (2021) (23)
- Transglutaminase 2 Expression Predicts Progression Free Survival in Non-Small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (2013) (23)
- Primary Idiopathic Chylopericardium Associated with Cervicomediastinal Cystic Hygroma (2005) (23)
- CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study (2017) (23)
- Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice (2021) (22)
- CNS response to osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFR-TKI sensitising mutation (EGFRm)-positive advanced non-small cell lung cancer (NSCLC): Data from the FLAURA study. (2017) (22)
- Dual-targeting of EGFR and Neuropilin-1 Attenuates Resistance to EGFR-targeted Antibody Therapy in KRAS-mutant Non-Small Cell Lung Cancer. (2019) (22)
- Exome sequencing reveals recurrent REV3L mutations in cisplatin-resistant squamous cell carcinoma of head and neck (2016) (22)
- Three-year overall survival update from the PACIFIC trial. (2019) (21)
- RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation (2018) (21)
- Transoral robotic surgery-based therapy in patients with stage III-IV oropharyngeal squamous cell carcinoma. (2017) (21)
- Abstract 442: Repotrectinib, a next generation TRK inhibitor, overcomes TRK resistance mutations including solvent front, gatekeeper and compound mutations (2019) (20)
- A phase Ib study of the combination of afatinib and ruxolitinib in EGFR mutant NSCLC with progression on EGFR-TKIs. (2019) (20)
- A phase I trial of gefitinib and nimotuzumab in patients with advanced non-small cell lung cancer (NSCLC). (2012) (20)
- PIK3CA amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma (2016) (20)
- Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy. (2019) (20)
- Safety and Efficacy of Dacomitinib in Korean Patients with KRAS Wild-Type Advanced Non–Small-Cell Lung Cancer Refractory to Chemotherapy and Erlotinib or Gefitinib: A Phase I/II Trial (2014) (19)
- Indoor radon exposure increases tumor mutation burden in never-smoker patients with lung adenocarcinoma. (2019) (19)
- Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib (2012) (19)
- Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity (2018) (19)
- Alteration status and prognostic value of MET in head and neck squamous cell carcinoma (2016) (19)
- Nivolumab in advanced non-small-cell lung cancer patients who failed prior platinum-based chemotherapy. (2018) (19)
- Efficacy of entrectinib in patients (pts) with solid tumors and central nervous system (CNS) metastases: Integrated analysis from three clinical trials. (2019) (19)
- Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade. (2020) (19)
- Role of FGF receptors as an emerging therapeutic target in lung squamous cell carcinoma. (2013) (18)
- The promise of bispecific antibodies: Clinical applications and challenges. (2021) (18)
- Landscape of genomic alterations (GA) and tumor mutational burden (TMB) in different metastatic melanoma (MM) subtypes. (2017) (18)
- Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. (2018) (18)
- A phase 1 study of the next-generation ALK/ROS1/TRK inhibitor ropotrectinib (TPX-0005) in patients with advanced ALK/ROS1/NTRK+ cancers (TRIDENT-1). (2018) (18)
- Three-year overall survival update from the PACIFIC trial (2019) (18)
- Establishment of a Conditional Transgenic Mouse Model Recapitulating EML4‐ALK–Positive Human Non–Small Cell Lung Cancer (2017) (18)
- Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in patients with TKI-naïve, EGFRm NSCLC with CNS metastases. (2017) (18)
- Durvalumab With or Without Tremelimumab in Combination With Chemotherapy as First-Line Therapy for Metastatic Non–Small-Cell Lung Cancer: The Phase III POSEIDON Study (2022) (18)
- Architectural patterns of p16 immunohistochemical expression associated with cancer immunity and prognosis of head and neck squamous cell carcinoma (2017) (18)
- Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases From Lung Adenocarcinoma (2015) (18)
- Concordance of programmed death-ligand 1 expression between primary and metastatic non-small cell lung cancer by immunohistochemistry and RNA in situ hybridization (2017) (17)
- Antitumor Activity and Acquired Resistance Mechanism of Dovitinib (TKI258) in RET-Rearranged Lung Adenocarcinoma (2015) (17)
- A phase II trial of fractionated irinotecan plus carboplatin for previously untreated extensive-disease small cell lung cancer. (2006) (17)
- Phase Ib/II study of the pan-cyclin-dependent kinase inhibitor roniciclib in combination with chemotherapy in patients with extensive-disease small-cell lung cancer. (2018) (17)
- Prognostic Factors in Small Cell Lung Cancer: A New Prognostic Index in Korean Patients (2011) (17)
- NCIC CTG BR.26: A phase III randomized, double blind, placebo controlled trial of dacomitinib versus placebo in patients with advanced/metastatic non-small cell lung cancer (NSCLC) who received prior chemotherapy and an EGFR TKI. (2014) (17)
- Efficacy and safety of vinorelbine plus cisplatin chemotherapy for patients with recurrent and/or metastatic salivary gland cancer of the head and neck (2018) (17)
- Correlation Between 18F-Fluorodeoxyglucose Uptake and Epidermal Growth Factor Receptor Mutations in Advanced Lung Cancer (2012) (17)
- Chemoradiotherapy with or without consolidation chemotherapy using cisplatin and 5-fluorouracil in anal squamous cell carcinoma: long-term results in 31 patients (2008) (17)
- The feasibility and safety of radical esophagectomy in patients receiving neoadjuvant chemoradiotherapy with pembrolizumab for esophageal squamous cell carcinoma (2020) (17)
- Efficacy and Toxicity of Belotecan for Relapsed or Refractory Small Cell Lung Cancer Patients (2012) (17)
- ASTRIS: A real world treatment study of osimertinib in patients (pts) with EGFR T790M positive non-small cell lung cancer (NSCLC). (2017) (16)
- Osimertinib, an Irreversible Next-Generation EGFR Tyrosine Kinase Inhibitor, Exerts Antitumor Activity in Various Preclinical NSCLC Models Harboring the Uncommon EGFR Mutations G719X or L861Q or S768I (2020) (16)
- Ei24-deficiency attenuates protein kinase Cα signaling and skin carcinogenesis in mice. (2012) (16)
- The Impact of Cigarette Smoking on the Frequency of and Qualitative Differences in KRAS Mutations in Korean Patients with Lung Adenocarcinoma (2013) (16)
- Patient-Derived Cells to Guide Targeted Therapy for Advanced Lung Adenocarcinoma (2019) (16)
- Real-World Analysis of the Efficacy of Rebiopsy and EGFR Mutation Test of Tissue and Plasma Samples in Drug-Resistant Non-Small Cell Lung Cancer (2019) (16)
- OA 05.07 Efficacy and Updated Safety of Ceritinib (450 Mg or 600 Mg) with Low-Fat Meal vs 750 Mg Fasted in ALK+ Metastatic NSCLC (2017) (15)
- Rare Incidence of ROS1 Rearrangement in Cholangiocarcinoma (2016) (15)
- A Clinical Trial of Combination Neoadjuvant Chemotherapy and Transoral Robotic Surgery in Patients with T3 and T4 Laryngo-Hypopharyngeal Cancer (2018) (15)
- Molecular Screening of Small Biopsy Samples Using Next-Generation Sequencing in Korean Patients with Advanced Non-small Cell Lung Cancer: Korean Lung Cancer Consortium (KLCC-13-01) (2018) (15)
- Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer (2007) (15)
- Blood tumor mutational burden (bTMB) and tumor PD-L1 as predictive biomarkers of survival in MYSTIC: First-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic (m) NSCLC. (2019) (15)
- A Phase 1/2 Study of Lazertinib 240 mg in Patients with Advanced EGFR T790M-Positive Non-Small Cell Lung Cancer After Prior EGFR Tyrosine Kinase Inhibitors (2021) (15)
- BOS172738, a highly potent and selective RET inhibitor, for the treatment of RET-altered tumors including RET-fusion+ NSCLC and RET-mutant MTC: Phase 1 study results. (2021) (15)
- Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors (2018) (15)
- Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial. (2020) (15)
- 410O_PRAlectinib (ALC) vs crizotinib (CRZ) in treatment-naïve ALK+ non-small-cell lung cancer (NSCLC): Asian vs non-Asian subgroup analysis of the ALEX study (2017) (14)
- Phase I study (BLOOM) of AZD3759, a BBB penetrable EGFR inhibitor, in EGFRm NSCLC patients with leptomeningeal metastasis (LM) who progressed after other anti-cancer therapy. (2017) (14)
- First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study. (2022) (14)
- Optimal Adjuvant Treatment for Curatively Resected Thoracic Esophageal Squamous Cell Carcinoma: A Radiotherapy Perspective (2016) (14)
- Combination of topotecan and etoposide as a salvage treatment for patients with recurrent small cell lung cancer following irinotecan and platinum first-line chemotherapy (2007) (14)
- Brief Report: Osimertinib Plus Durvalumab in Patients with EGFR-Mutated, Advanced Non-Small Cell Lung Cancer: A Phase 1b, Open-Label, Multicenter Trial. (2022) (14)
- Mouse–human co-clinical trials demonstrate superior anti-tumour effects of buparlisib (BKM120) and cetuximab combination in squamous cell carcinoma of head and neck (2020) (14)
- A multicenter phase II study of sorafenib in combination with erlotinib in patients with advanced non-small cell lung cancer (KCSG-0806). (2016) (14)
- Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). (2021) (13)
- Abstract CT075: Phase I evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus (HPV)-associated malignancies (2019) (13)
- Molecular characterization of lung adenocarcinoma from Korean patients using next generation sequencing (2019) (13)
- JNJ-61186372 (JNJ-372), an EGFR-cMET bispecific antibody, in advanced non-small cell lung cancer (NSCLC): An update on phase I results. (2018) (13)
- Subacute bacterial endocarditis associated with upper endoscopy. (2004) (13)
- Twist and Snail/Slug Expression in Oropharyngeal Squamous Cell Carcinoma in Correlation With Lymph Node Metastasis (2019) (13)
- Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response (2020) (13)
- Abstract CT060: STARTRK-2: A global phase 2, open-label, basket study of entrectinib in patients with locally advanced or metastatic solid tumors harboring TRK, ROS1, or ALK gene fusions (2017) (13)
- Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma (2015) (13)
- 1193MO Amivantamab plus lazertinib in post-osimertinib, post-platinum chemotherapy EGFR-mutant non-small cell lung cancer (NSCLC): Preliminary results from CHRYSALIS-2 (2021) (12)
- P3.02b-001 Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC: Topic: EGFR Biomarkers (2017) (12)
- A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (2016) (12)
- Real-world treatment patterns and clinical outcomes in patients with stage III non-small cell lung cancer: Results of KINDLE, a multi-country observational study. (2021) (12)
- Abstract CT033: TATTON Phase Ib expansion cohort: Osimertinib plus savolitinib for patients (pts) withEGFR-mutant,MET-amplified NSCLC after progression on prior third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) (2019) (12)
- Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2. (2019) (12)
- Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis (2017) (12)
- Results from a second-line (2L) NSCLC cohort treated with M7824 (MSB0011359C), a bifunctional fusion protein targeting TGF-β and PD-L1. (2018) (12)
- Weekly 5‐fluorouracil plus cisplatin for concurrent chemoradiotherapy in patients with locally advanced head and neck cancer (2009) (12)
- Targeting RET in patients with RET-rearranged lung cancers: Results from a global registry. (2016) (12)
- Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: a phase II trial. (2010) (12)
- A Pilot Study of Trans-Arterial Injection of 166Holmium-Chitosan Complex for Treatment of Small Hepatocellular Carcinoma (2005) (12)
- Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection (2018) (12)
- 1192MO Amivantamab monotherapy and in combination with lazertinib in post-osimertinib EGFR-mutant NSCLC: Analysis from the CHRYSALIS study (2021) (11)
- Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer (2020) (11)
- Amivantamab and lazertinib in patients with EGFR-mutant non–small cell lung (NSCLC) after progression on osimertinib and platinum-based chemotherapy: Updated results from CHRYSALIS-2. (2022) (11)
- Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study. (2018) (11)
- Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR. (2014) (11)
- developmental therapeuticsPhase I study of the pan-fibroblast growth factor receptor (FGFR) inhibitor BAY 1163877 with expansion cohorts for subjects based on tumor FGFR mRNA expression levels (2016) (11)
- Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma (2020) (11)
- Allosteric Inhibitor TREA-0236 Containing Non-hydrolysable Quinazoline-4-one for EGFR T790M/C797S Mutants Inhibition (2018) (11)
- Phase II study of camtobell inj. (belotecan) in combination with cisplatin in patients with previously untreated, extensive stage small cell lung cancer. (2013) (11)
- Amivantamab in patients with NSCLC with MET exon 14 skipping mutation: Updated results from the CHRYSALIS study. (2022) (10)
- Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung (2013) (10)
- Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer (2020) (10)
- Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC. (2019) (10)
- P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC (2021) (10)
- Prognostic Factors in Early-stage NSCLC: Analysis of the Placebo Group in the MAGRIT Study (2019) (10)
- Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA (2019) (10)
- Clinical decision support algorithm based on machine learning to assess the clinical response to anti-programmed death-1 therapy in patients with non-small-cell lung cancer. (2021) (10)
- Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy (2016) (10)
- M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-β, in patients (pts) with advanced SCCHN: Results from a phase I cohort. (2018) (10)
- 1239P ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib (2021) (10)
- Paclitaxel and leucovorin-modulated infusional 5-fluorouracil combination chemotherapy for metastatic gastric cancer. (2006) (10)
- Ceritinib in ROS1-rearranged non-small-cell lung cancer: a Korean nationwide phase II study (2016) (10)
- The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer (2007) (10)
- The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC. (2008) (10)
- Efficacy and safety of the antibody-drug conjugate (ADC) SAR408701 in patients (pts) with non-squamous non-small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). (2020) (10)
- Efficacy and safety of atezolizumab, in combination with etoposide and carboplatin regimen, in the first-line treatment of extensive-stage small-cell lung cancer: a single-center experience (2021) (10)
- Real-world use of osimertinib in non–small cell lung cancer: ASTRIS study Korean subgroup analysis (2020) (9)
- Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma (2020) (9)
- Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers. (2017) (9)
- Patient-Reported Outcomes with Durvalumab With or Without Tremelimumab Versus Standard Chemotherapy as First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer (MYSTIC). (2021) (9)
- Abstract CT302: Phase Ia/Ib dose-escalation study of the anti-TIGIT antibody tiragolumab as a single agent and in combination with atezolizumab in patients with advanced solid tumors (2020) (9)
- Effect of post-study immunotherapy (IO) on overall survival (OS) outcome in patients with metastatic (m) NSCLC treated with first-line durvalumab (D) vs chemotherapy (CT) in the phase III MYSTIC study. (2019) (9)
- The CANOPY program: Canakinumab in patients (pts) with non-small cell lung cancer (NSCLC). (2019) (9)
- FP03.02 Interim Analysis of Neoadjuvant Chemoradiotherapy and Durvalumab for Potentially Resectable Stage III Non-Small Cell Lung Cancer (NSCLC) (2021) (9)
- High CD3 and ICOS and low TIM-3 expression predict favourable survival in resected oesophageal squamous cell carcinoma (2019) (9)
- CHRYSALIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC. (2021) (9)
- Detection of activating and acquired resistant mutation in plasma from EGFR-mutated NSCLC patients by peptide nucleic acid (PNA) clamping-assisted fluorescence melting curve analysis. (2017) (9)
- Three-Year Follow-Up and Response–Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3) (2022) (9)
- Randomized phase II study comparing weekly docetaxel-cisplatin vs. gemcitabine-cisplatin in elderly or poor performance status patients with advanced non-small cell lung cancer (2017) (9)
- A randomized phase II trial of ERCC1 and RRM1 mRNA expression-based chemotherapy versus docetaxel/carboplatin in advanced non-small cell lung cancer (2016) (9)
- A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) (2019) (8)
- 957O Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1 (2021) (8)
- Molecular landscape of osimertinib resistance revealed by targeted panel sequencing and patient-derived cancer models in non-small cell lung cancer patients. (2018) (8)
- Reduced expression of EI24 confers resistance to gefitinib through IGF-1R signaling in PC9 NSCLC cells. (2015) (8)
- The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer. (2015) (8)
- OA15.03 Amivantamab in Non-small Cell Lung Cancer (NSCLC) with MET Exon 14 Skipping (METex14) Mutation: Initial Results from CHRYSALIS (2021) (8)
- OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) (2018) (8)
- SKYSCRAPER-07: A phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. (2022) (8)
- P3.02a-036 Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC: Topic: Miscellaneous (2017) (7)
- Abstract CT113: Safety and activity of second-line durvalumab + tremelimumab in non-squamous advanced NSCLC (2018) (7)
- EGFR-Mediated Reactivation of MAPK Signaling Induces Acquired Resistance to GSK2118436 in BRAF V600E–Mutant NSCLC Cell Lines (2016) (7)
- Abstract PR07: AZD9291 activity in patients with leptomeningeal disease from non-small cell lung cancer: a Phase I study (2015) (7)
- Optimal dose and volume for postoperative radiotherapy in brain oligometastases from lung cancer: a retrospective study (2017) (7)
- Updated results of M7824 (MSB0011359C): A bifunctional fusion protein targeting TGF-β and PD-L1, in second-line (2L) NSCLC. (2018) (7)
- Impact of a planned dose interruption of dacomitinib in the treatment of advanced non-small-cell lung cancer (ARCHER 1042). (2017) (7)
- Validation of ALK/ROS1 Dual Break Apart FISH Probe probe in non-small-cell lung cancer. (2017) (7)
- ER2, a novel human anti-EGFR monoclonal antibody inhibit tumor activity in non-small cell lung cancer models. (2016) (7)
- The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges (2022) (7)
- P3.02b-119 YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC: Topic: EGFR RES (2017) (7)
- Three-year follow-up of ATTRACTION-3: A phase III study of nivolumab (Nivo) in patients with advanced esophageal squamous cell carcinoma (ESCC) that is refractory or intolerant to previous chemotherapy. (2021) (7)
- Intracranial anti-tumor activity of lazertinib in patients with advanced NSCLC who progressed after prior EGFR TKI therapy: Data from a phase I/II study. (2020) (7)
- Real-World Experience of Nivolumab in Non-small Cell Lung Cancer in Korea (2020) (7)
- A phase II study of poziotinib in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (2021) (6)
- MA11.05 Tepotinib in Patients with MET exon 14 (METex14) Skipping Advanced NSCLC: Updated Efficacy Results from VISION Cohort A (2021) (6)
- Afatinib in heavily pretreated advanced NSCLC patients who progressed following prior gefitinib or erlotinib: Compassionate use program in Korea. (2018) (6)
- Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC (2019) (6)
- Patritumab Deruxtecan: Paving the Way for EGFR-TKI-Resistant NSCLC. (2022) (6)
- Abstract 4897: Detection of MET-mediated EGFR tyrosine kinase inhibitor (TKI) resistance in advanced non-small cell lung cancer (NSCLC): biomarker analysis of the TATTON study (2019) (6)
- A Case of Synchronous Squamous Cell Carcinoma in the Esophagus and Stomach (2012) (6)
- Five-Year Outcomes With Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients With Non–Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study (2022) (6)
- 1194MO Canakinumab (CAN) + docetaxel (DTX) for the second- or third-line (2/3L) treatment of advanced non-small cell lung cancer (NSCLC): CANOPY-2 phase III results (2021) (6)
- Lack of ROS1 Gene Rearrangement in Glioblastoma Multiforme (2015) (6)
- Structure–Activity Relationship Study of 2,4‐Dianilinopyrimidine Containing Methanesulfonamide (TRE‐069) as Potent and Selective Epidermal Growth Factor Receptor T790M/C797S Mutant Inhibitor for Anticancer Treatment (2017) (6)
- Cardiac Safety Assessment of Lazertinib: Findings From Patients With EGFR Mutation-Positive Advanced NSCLC and Preclinical Studies (2021) (6)
- Distinct Characteristics and Clinical Outcomes to Predict the Emergence of MET Amplification in Patients with Non-Small Cell Lung Cancer Who Developed Resistance after Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (2021) (6)
- 1288P Efficacy of entrectinib in patients with NTRK or ROS1 fusion-positive NSCLC with CNS metastases at baseline (2020) (5)
- The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (2012) (5)
- CANOPY-A: A phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating canakinumab as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC). (2020) (5)
- The Role of Monoclonal Antibody in Combination with First-Line Chemotherapy in Asian Patients with Advanced Non-Small Cell Lung Cancer (2009) (5)
- 363 Vactosertib and durvalumab as second or later line treatment for PD-L1 positive non-small cell lung cancer: interim result (2020) (5)
- Primary efficacy and biomarker analyses from the VISION study of tepotinib in patients (pts) with non-small cell lung cancer (NSCLC) with METex14 skipping. (2020) (5)
- PL 02.02 Patient-Reported Outcomes with Durvalumab after Chemoradiation in Locally Advanced, Unresectable NSCLC: Data from PACIFIC (2017) (5)
- Durvalumab in ≥ 3rd-line advanced NSCLC: Updated results from the phase 2 ATLANTIC study. (2018) (5)
- TRIDENT-1: A global, multicenter, open-label Phase II study investigating the activity of repotrectinib in advanced solid tumors harboring ROS1 or NTRK1-3 rearrangements. (2020) (5)
- 1256TiP Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012 (2020) (5)
- Two-year follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, for second-line (2L) treatment of non-small cell lung cancer (NSCLC). (2020) (5)
- 139PD Patient-reported outcomes from FLAURA: Osimertinib versus standard of care (SoC) epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) (2018) (5)
- Predicting treatment outcomes using 18F-FDG PET biomarkers in patients with non-small-cell lung cancer receiving chemoimmunotherapy (2022) (5)
- Predictive factors for the development of diabetes in cancer patients treated with phosphatidylinositol 3-kinase inhibitors (2019) (5)
- Tumor MET expression profile predicts the outcome of non‐small cell lung cancer patients receiving epidermal growth factor receptor tyrosine kinase inhibitors (2014) (5)
- Early clinical experience with the pan-FGFR inhibitor rogaratinib in patients with non-small cell lung cancer selected based on FGFR mRNA expression levels. (2019) (5)
- 384P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC (2020) (5)
- FP13.01 5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC (2021) (5)
- Tepotinib in NSCLC patients harboring METex14 skipping: Cohort A of phase II VISION study (2019) (5)
- Olmutinib in T790M‐positive non–small cell lung cancer after failure of first‐line epidermal growth factor receptor‐tyrosine kinase inhibitor therapy: A global, phase 2 study (2021) (5)
- The Clinical Usefulness of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) to Predict Oncologic Outcomes and PET-Based Radiotherapeutic Considerations in Locally Advanced Nasopharyngeal Carcinoma (2015) (5)
- Induction docetaxel and S‐1 followed by concomitant radiotherapy with low‐dose daily cisplatin in locally advanced head and neck carcinoma (2016) (5)
- P2.06-017 Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET: Topic: Phase II + NK (2017) (5)
- VP3-2021: A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small-cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial (2021) (4)
- CANOPY-A: A phase III study of canakinumab as adjuvant therapy in patients with surgically resected non-small cell lung cancer (NSCLC). (2019) (4)
- Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC). (2022) (4)
- YH25448, a 3rd generation EGFR-TKI, in patients with EGFR-TKI-resistant NSCLC: Phase I/II study results. (2018) (4)
- DGG-100629 inhibits lung cancer growth by suppressing the NFATc1/DDIAS/STAT3 pathway (2021) (4)
- First subsequent treatment after discontinuation of durvalumab in unresectable, stage III NSCLC patients from PACIFIC. (2019) (4)
- Abstract 1467: BLU-945, a fourth-generation, potent and highly selective epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) with intracranial activity, demonstrates robustin vivoantitumor activity in models of osimertinib-resistant non-small cell lung cancer (NSCLC) (2021) (4)
- Clinical trials outcomes of combined BKM120 and cetuximab compared to BKM120 in recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN). (2015) (4)
- Phase II Trial of Afatinib as a Third-Line Treatment for Korean Patients (PTS) with Wild-Type Epidermal Growth Factor Receptor (WTEGFR) Stage IIIB/IV Lung Adenocarcinoma (2012) (4)
- Dynamic changes in circulating PD-1+CD8+ T lymphocytes for predicting treatment response to PD-1 blockade in patients with non-small cell lung cancer. (2020) (4)
- Primary efficacy and updated safety of ceritinib (450mg or 600mg) with food vs 750mg fasted in ALK+ metastatic NSCLC (ASCEND-8). (2018) (4)
- LBA1_PRPACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC (2017) (4)
- Efficacy and safety of dovitinib in pretreated advanced squamous non-small cell lung cancer with FGFR1 amplification: A single-arm, phase II study (2016) (4)
- Osimertinib in Patients with T790M-Positive Advanced Non-small Cell Lung Cancer: Korean Subgroup Analysis from Phase II Studies (2019) (4)
- NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma (2019) (4)
- Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer. (2021) (4)
- Abstract CT192: Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2 (2019) (4)
- Long-Term Efficacy and Safety of Entrectinib in ROS1 Fusion–Positive NSCLC (2022) (4)
- CANOPY-1: A phase III, placebo-controlled study of pembrolizumab (PEM) plus platinum-based doublet chemotherapy (Ctx) with/without canakinumab in untreated patients (pts) with stage IIIB/IIIC-IV NSCLC (2019) (3)
- Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation. (2018) (3)
- Efficacy and safety of lazertinib 240 mg as the clinical dose in patients with EGFR T790M mutant NSCLC: Data from a phase I/II study. (2020) (3)
- Rationale and Design of the Phase III KEYLYNK-012 Study of Pembrolizumab and Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Stage III Non-Small-Cell Lung Cancer. (2022) (3)
- Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT). (2018) (3)
- LBA6_PROsimertinib vs standard of care (SoC) EGFR-TKI as first-line treatment in patients with EGFR-TKI sensitising mutation (EGFRm) positive advanced non-small cell lung cancer (NSCLC): FLAURA Asian subset (2017) (3)
- Anticancer effect of verteporfin on non-small cell lung cancer via downregulation of ANO1. (2022) (3)
- Chemoradiation and maintenance chemotherapy with cisplatin and 5-fluorouracil in anal squamous cell carcinoma. (2006) (3)
- Abstract 1826: Comprehensive preclinical study on GI-101, a novel CD80-IgG4-IL2 variant protein, as a therapeutic antibody candidate with bispecific immuno-oncology target (2021) (3)
- Abstract 3385: Liquid biopsy to detectMETexon 14 skipping (METex14) andMETamplification in patients with advanced NSCLC: Biomarker analysis from VISION study (2020) (3)
- 1689P Adverse event management during treatment with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1: Treatment guidelines based on experience in clinical trials (2021) (3)
- Genomic Landscape of Non-Small Cell Lung Cancer (NSCLC) in East Asia Using Circulating Tumor DNA (ctDNA) in Clinical Practice (2022) (3)
- P2.06-003 A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non-Small Cell Lung Cancer (NSCLC) Progressed on EGFR-TKI: Topic: Phase I Trials (2017) (3)
- Contemporary management and associated outcomes of 3,151 patients with stage III non-small cell lung cancer (NSCLC) in a real-world setting: Results of KINDLE, a multicountry observational study. (2020) (3)
- Prospective validation of prognostic scores to improve patient selection for immuno-oncology trials. (2018) (3)
- Molecular landscape of osimertinib resistance in patients and patient-derived preclinical models (2022) (3)
- SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models (2021) (3)
- Brief Report: Heterogeneity of Acquired Resistance Mechanisms to Osimertinib and Savolitinib (2021) (3)
- Analyses of CNS Response to Osimertinib in Patients with T790M-Positive Advanced NSCLC from ASTRIS Korean Subset, Open-Label Real-World Study (2021) (3)
- MORPHEUS: A phase Ib/II multi-trial platform evaluating the safety and efficacy of cancer immunotherapy (CIT)-based combinations in patients (pts) with non-small cell lung cancer (NSCLC). (2018) (3)
- P86.12 Cardiac Safety Assessment of Lazertinib in Patients with EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer (2021) (2)
- Abstract 5199: JNJ-61186372, an EGFR-cMet bispecific antibody, in EGFR Exon 20 insertion-driven advanced non-small cell lung cancer (NSCLC) (2020) (2)
- Patient-reported outcomes (PROs) with first-line durvalumab (D) ± tremelimumab (T) versus chemotherapy (CT) in metastatic NSCLC: Results from MYSTIC. (2019) (2)
- Phase II study of cisplatin with irinotecan as induction chemotherapy followed by chemoradiotherapy for unresectable stage III non-small cell lung cancer. (2012) (2)
- 470 A phase 1/2, open-label, dose escalation and expansion study of GI-101 as a single agent and in combination with a pembrolizumab, lenvatinib or local RT in advanced solid tumors (KEYNOTE-B59) (2021) (2)
- 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer (2021) (2)
- P3.02b-005 Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results: Topic: EGFR Biomarkers (2017) (2)
- OA05.03 Real-World Global Data on Targeting Epidermal Growth Factor Receptor in Stage III Non-Small Cell Lung Cancer: The Results of the KINDLE Study (2021) (2)
- Can We Prevent Resistance to Osimertinib? Combination or Sequential. (2018) (2)
- 379PA novel mRNA-based patient selection strategy identifies fibroblast growth factor receptor (FGFR) inhibitor-sensitive tumors: Results from rogaratinib Phase-1 study (2017) (2)
- Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer (2023) (2)
- Antibody–Drug Conjugates: A New Addition to the Treatment Landscape of EGFR-Mutant Non–Small Cell Lung Cancer (2022) (2)
- DNA methylome and single-cell transcriptome analyses reveal CDA as a potential druggable target for ALK inhibitor–resistant lung cancer therapy (2022) (2)
- FP14.10 Efficacy and Safety of Selpercatinib (LOXO-292) in East Asian Patients with RET Fusion-Positive NSCLC (2021) (2)
- Predictive factors of early distant brain failure after gamma knife radiosurgery alone in patients with brain metastases of non-small-cell lung cancer (2017) (2)
- 1315P Phase Ib/II open-label, randomised evaluation of atezolizumab (atezo) + CPI-444 vs docetaxel as second/third-line therapy in MORPHEUS-NSCLC (non-small cell lung cancer) (2020) (2)
- Rationale and Design of the Phase 3 KEYLYNK-013 Study of Pembrolizumab With Concurrent Chemoradiotherapy Followed by Pembrolizumab With or Without Olaparib for Limited-Stage Small-Cell Lung Cancer. (2022) (2)
- A Case of Successful Intrapleural Chemotherapy with Cisplatin Plus Cytarabine for Intractable Malignant Pleural Effusion (2007) (2)
- Continuous centrifugal microfluidics (CCM) isolates heterogeneous circulating tumor cells via full automation (2022) (2)
- 281 JAVELIN Medley VEGF: phase 2 study of avelumab + axitinib in patients with previously treated non-small cell lung cancer (NSCLC) or treatment naive, cisplatin-ineligible urothelial cancer (UC) (2020) (2)
- Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET-Amplified Non–Small Cell Lung Cancer: TATTON (2022) (2)
- Health-related quality of life (HRQoL) of pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase III KEYNOTE-590 study. (2021) (2)
- A Multicenter Two-arm, Phase II Trial Assessing the Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer (ABLATE, KCSG-LU21-11). (2022) (2)
- Results From a Phase I Study of MK-1308 (ANTI–CTLA-4) Plus Pembrolizumab in Previously Treated Advanced Small Cell Lung Cancer (2019) (2)
- Phase 1b Open-Label Trial of Afatinib Plus Xentuzumab (BI 836845) in Patients With EGFR Mutation-Positive NSCLC After Progression on EGFR Tyrosine Kinase Inhibitors (2021) (2)
- Abstract CT201: Phase Ib/II open-label, randomized evaluation of atezolizumab + cobimetinib vs control in MORPHEUS-NSCLC (non-small cell lung cancer), MORPHEUS-PDAC (pancreatic ductal adenocarcinoma) and MORPHEUS-GC (gastric cancer) (2020) (2)
- A man with recurrent hypovolemic shock on anti-programmed cell death protein 1 treatment: Immune-related protein-losing enteropathy. (2018) (2)
- Phase I/II Trial (2020) (2)
- Acquired EGFR C 797 S mediates resistance to AZD 9291 in advanced non-small cell lung cancer harboring EGFR T 790 M (2016) (2)
- Management of infusion-related reactions (IRRs) in patients receiving amivantamab in the CHRYSALIS study. (2023) (2)
- KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC. (2021) (2)
- Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. (2023) (2)
- Safety and efficacy of tusamitamab ravtansine (SAR408701) in long-term treated patients with nonsquamous non–small cell lung cancer (NSQ NSCLC) expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5). (2022) (2)
- CANOPY-2: A phase III, placebo-controlled study of canakinumab with or without docetaxel in patients (pts) with NSCLC previously treated with PD-(L)1 inhibitors and platinum-based chemotherapy (Ctx) (2019) (1)
- 383MO Tepotinib in Asian patients (pts) with advanced NSCLC with MET exon 14 (METex14) skipping (2020) (1)
- Abstract 4663: Acquired resistance to gefitinib is associated with cancer stem-like phenotype and EMT in EGFR mutant lung adenocarcinoma. (2013) (1)
- P76.18 Tissue- and Plasma-Based Landscape of Resistance to Osimertinib (2021) (1)
- Abstract 2856: Fibroblast growth factor receptor 1 gene amplification as an independent prognostic factor for recurrence in patients with resected squamous cell esophageal cancer (2014) (1)
- Abstract 683: A machine learning based clinical decision support system (CDSS) for anti-PD-1 therapy using non-invasive blood marker and clinical information for lung cancer patients (2019) (1)
- KEYLYNK-012: A Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy (CCRT) Followed by Pembrolizumab With or Without Olaparib vs. CCRT Followed by Durvalumab in Unresectable, Locally Advanced, Stage III Non‒Small-Cell Lung Cancer. (2021) (1)
- Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012. (2021) (1)
- Interim analysis for window of opportunity trial of single dose preoperative durvalumab (D) with or without tremelimumab (T) for operable head and neck squamous cell carcinoma (HNSCC). (2021) (1)
- Abstract 5198: JNJ-61186372, a novel EGFR/c-Met bispecific antibody, exhibits potent antitumor activity in broad-spectrum of acquired resistance to EGFR-TKIs (2020) (1)
- P14.01 Phase 3 Study of First-Line Pembrolizumab ± Vibostolimab (anti-TIGIT) in Patients With PD-L1‒Positive Metastatic NSCLC (2021) (1)
- A machine learning based prediction model of anti-PD-1 therapy response using noninvasive clinical information and blood markers of lung cancer patients. (2019) (1)
- BIW-8962, an Anti GM2 Ganglioside Monoclonal Antibody, in Previously Treated Advanced/Recurrent Lung Cancer: a Phase I/II Study (2018) (1)
- Neoadjuvant therapy for thymic neoplasms reduces tumor volume per 3D-reconstructed images but does not improve the complete resection rate (2019) (1)
- Abstract 38: NSCLC patient-derived organoids to guide personalized therapy (2019) (1)
- Abstract 5012: Mouse-human co-clinical trials demonstrate superior efficacy with combinational approach of BKM120 and erbitux over BKM120 monotherapy in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN) (2017) (1)
- Abstract 713: Upregulation of immune checkpoint molecules on Treg cells in tumor microenvironment reinforces immune exhaustion in cancer patients (2018) (1)
- Abstract LB078: Tumor genomics in patients (pts) with advanced epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib therapy in the Phase II ORCHARD study (2022) (1)
- Amivantamab, an Epidermal Growth Factor Receptor (EGFR) and Mesenchymal-epithelial Transition Factor (MET) Bispecific Antibody, Designed to Enable Multiple Mechanisms of Action and Broad Clinical Applications. (2022) (1)
- P1.02-030 Performance Evaluation of ALK/ROS1 Dual Break Apart FISH Probe Kit (RUO) in Non-Small-Cell Lung Cancer: Topic: Driver Genes in NSCLC, Resistance, and Other (2017) (1)
- Phase II study of oral S-1 monotherapy in metastatic colorectal cancer after failure of both irinotecan and oxaliplatin-containing regimen. (2006) (1)
- Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study. (2021) (1)
- Abstract 3942: Oncogenic BRAF fusion induces MAPK-pathway activation targeted by MEK inhibitor and phosphatidylinositol 3-kinase inhibitor combination treatment in mucosal melanoma (2015) (1)
- O13-3 Tepotinib in patients with MET exon 14 (METex14) skipping advanced NSCLC: Updated efficacy results from VISION cohort A (2021) (1)
- Phase II Study of Afatinib as Third-Line Treatment for Patients in Korea With Stage IIIB/IV Non-Small Cell Lung Cancer Harboring Wild-Type EGFR. (2015) (1)
- Abstract 6529: GI101, A novel CD80-IgG4-IL2 variant bispecific protein, inhibits tumor growth and induces anti-tumor immune response in multiple preclinical models (2020) (1)
- A Case of Lactic Acidosis Caused by Stavudine in an AIDS Patient (2004) (1)
- Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target? (2021) (1)
- Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN). (2021) (1)
- Abstract CT198: Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: Initial safety and pharmacokinetic results from the PALOMA study (2022) (1)
- ctDNA resistance landscape of lazertinib, a third-generation EGFR tyrosine kinase inhibitor (TKI). (2020) (1)
- Lazertinib: on the Way to Its Throne (2022) (1)
- Real-world global data on targeting epidermal growth factor receptor mutations in stage III non-small-cell lung cancer: the results of the KINDLE study (2022) (1)
- Abstract LB515A: A MET targeting biparatopic antibody-drug conjugates (ADC), REGN5093-M114, has an antitumor efficacy in NSCLC harboring MET gene alterations (2022) (1)
- 203 Preclinical characterization and development of MG1124, a Novel Immune Checkpoint inhibitor targeting CEACAM1 for NSCLC patients (2020) (1)
- A phase 1b/2 study of PF-06747775 as monotherapy or in combination with Palbociclib in patients with epidermal growth factor receptor mutant advanced non-small cell lung cancer (2022) (1)
- 3214 Second solid cancers after total body irradiation conditioning in children undergoing hematopoietic stem cell transplant (2015) (1)
- Identification of TRE‐130 as Reversible Inhibitor of Pan‐EGFR Mutants while Sparing EGFR Wild‐Type Activity (2019) (1)
- Intracranial failure after hippocampal-avoidance prophylactic cranial irradiation in limited-stage small-cell lung cancer patients (2021) (1)
- Abstract CT311: A randomized, open-label phase 2 study of efatutazone and erlotinib as second- or third-line therapy for non-small cell lung cancer (NSCLC) (2014) (1)
- Abstract CT303: The effect of savolitinib plus osimertinib on ctDNA clearance in patients with EGFR mutation positive (EGFRm)MET-amplified NSCLC in the TATTON study (2020) (1)
- Identification of somatic mutations in EGFR/KRAS/ALK-negative lung adenocarcinoma in never-smokers (2014) (1)
- Expert consensus recommendations on biomarker testing in metastatic and non-metastatic non-small cell lung cancer in Asia. (2022) (1)
- 371P Real-world insights into treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): KINDLE study India analysis (2020) (1)
- Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected in circulating tumor DNA (ctDNA) of non-small cell lung cancer (NSCLC) patients from East Asia. (2020) (1)
- 372P Treatment patterns and outcomes in stage III non-small cell lung cancer (NSCLC): Real-world experience in Singapore from the KINDLE study (2020) (1)
- Lazertinib, a 3rd generation EGFR-TKI, in patients with EGFR-TKI resistant NSCLC: Updated results of phase I/II Study. (2019) (1)
- Abstract CT286: CANOPY program clinical trials: Canakinumab (Cana) in patients (pts) with non-small cell lung cancer (NSCLC) (2020) (1)
- Antitumor activity and safety of MK-1308 (anti-CTLA-4) plus pembrolizumab (pembro) in patients (pts) with non-small cell lung cancer (NSCLC): Updated interim results from a phase I study. (2019) (1)
- P84.05 Efficacy and Safety of Ceritinib 450-mg Fed vs 750-mg Fasted in Patients with ALK+ NSCLC: Final Report of the ASCEND-8 Trial (2021) (1)
- MA 12.01 A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant NSCLC Progressed on EGFR-TKI: An Updated Analysis (2017) (1)
- P3-075: A phase II study of erlotinib treatment in advanced non-small cell lung cancer after failure of gefitinib: is a clinical benefit still achievable? (2007) (1)
- MA07.07 Ceritinib in ROS1-Rearranged Non-Small-Cell Lung Cancer: An Update of Korean Nationwide Phase II Study (2017) (1)
- A Phase 1b Study of Osimertinib Plus Savolitinib in Patients with EGFR Mutation-Positive, MET-Amplified, Non-Small Cell Lung Cancer after Progression on EGFR-Tyrosine Kinase Inhibitors (2019) (1)
- 1056P Durvalumab (D) in combination with chemoradiotherapy (CRT) in solid tumours: Phase I CLOVER study (2020) (1)
- Preclinical study of a biparatopic METxMET Antibody-Drug Conjugate, REGN5093-M114, overcomes MET-driven acquired resistance to EGFR TKIs in EGFR-mutant NSCLC. (2022) (1)
- Abstract 5408: Enhancement of the anti-tumor activity of afatinib by inhibition of glycolysis in non-small cell lung cancer harboring the EGFR T790M mutation . (2013) (1)
- Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response (2020) (1)
- Abstract 2266: Efficacy of CEACAM1-targeting immunoglobulin in combination with pembrolizumab in lung cancer (2019) (1)
- Role of cMET expression in non-small cell lung cancer patients treated with EGFR tyrosine kinase inhibitors. (2012) (1)
- Abstract 3527: Novel bacteria strains, CJRS-10671 and CJRS-10672, enhance anti-tumor efficacy in LLC1 syngeneic model and humanized PDX mice model (2022) (0)
- Abstract LB-123: Analysis of cell-free plasma DNA (cfDNA) identifies 3 molecular subtypes of acquired resistance to AZD9291, a novel EGFR tyrosine kinase inhibitor (TKI), in patients (pts) with advanced lung cancer (2015) (0)
- 442PSafety of nivolumab in patients with advanced or metastatic non-small cell lung cancer who have received at least one prior systemic regimens: Expanded access program in Korea (ONO-4538-X04) (2017) (0)
- Profiling of protein–protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors (2018) (0)
- Abstract 5481: Combination therapy with anti-PD-1 and YH29407, a novel IDO1 inhibitor, enhances T cell-mediated antitumor immunity in MC38 tumor-bearing mice (2022) (0)
- INDUCTION DOCETAXEL AND S-1 FOLLOWED BY CONCOMITANT RADIOTHERAPY WITH LOW-DOSE DAILY CISPLATIN IN LOCALLY ADVANCED HEAD AND NECK CARCINOMA (2011) (0)
- Durvalumab (D) +/- tremelimumab (T) + chemotherapy (CT) in first-line (1L) metastatic (m) NSCLC: AE management in POSEIDON. (2022) (0)
- SC21.04 Patient-Derived Xenografts for Guiding Therapy of Lung Cancer (2017) (0)
- Expert Consensus Recommendations on Biomarker Testing in Metastatic and Nonmetastatic NSCLC in Asia (2022) (0)
- Abstract LB-113: Enhanced anti-tumor efficacy of CEACAM1-targeting antibody after affinity maturation (2018) (0)
- Abstract CT282: KEYNOTE-975: A randomized, double-blind, placebo-controlled phase 3 trial of pembrolizumab vs placebo in participants with esophageal carcinoma receiving concurrent definitive chemoradiotherapy (2020) (0)
- Abstract 5712: Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade (2023) (0)
- 572 Fibroblast activating protein (FAP)-targeting IL-12 (anti-FAP/IL-12) TMEkine™ potentiates anti-cancer effects in preclinical cancer models (2020) (0)
- Comprehensive genomic profiling of circulating cell-free DNA (cfDNA) distinguishes focal amplification (amp) from aneuploidy among MET amps in diverse advanced cancer types. (2019) (0)
- Abstract 2369: Pharmacogenomic assessment of outcomes of pemetrexed-treated patients with adenocarcinoma of the lung. (2013) (0)
- Abstract 4022: Preclinical intracranial activity of NVL-655 in an alectinib-resistant patient-derived model harboring EML4-ALK fusion with G1202R mutation (2023) (0)
- P50.09 Characteristics and Clinical Outcomes of HER2 Mutated Non-small Cell Lung Cancer Patients Detected by NGS in Routine Clinical Practice (2021) (0)
- Genomic profiling of lung adenocarcinoma patients reveals potential therapeutic targets when standard molecular testing is negative. (2016) (0)
- Abstract 2010: SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune responses in various syngeneic cancer models (2019) (0)
- L858R epidermal growth factor receptor (EGFR) mutations as a favorable prognostic factor of relapse-free survival in resected non-small cell lung cancer (NSCLC) (2007) (0)
- 308P The genomic landscape of non-small cell lung cancer (NSCLC) in East Asia using circulating tumour DNA (ctDNA) in clinical practice (2020) (0)
- Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-mutant NSCLC: A Post-Hoc Subgroup Analysis from PACIFIC. (2023) (0)
- Abstract 4981: Comprehensive analysis of immune phenotypes identifies CD73+CD163highmacrophages as a prognostic biomarker in lung adenocarcinoma (2020) (0)
- Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy (2022) (0)
- 1312PTHE RELATIONSHIP BETWEEN EGFR AND KRAS MUTATION STATUS AND OVERALL SURVIVAL (OS) IN THE NCIC CTG BR.26 RANDOMIZED TRIAL OF DACOMITINIB (D) VERSUS PLACEBO (P) IN PATIENTS WITH PREVIOUSLY TREATED NON SMALL CELL LUNG CANCER (NSCLC). (2014) (0)
- Abstract 757: Activation of receptor-interacting serine/threonine protein kinase-2 (RIP2K) via EGFR-mediated CRAF transactivation induces the acquired resistance to Dabrafenib in BRAF V600E mutant non-small cell lung cancer (2015) (0)
- Abstract 3325: Intratumoral STING activation on artificially generated cutaneous metastasis of EML4-ALK lung cancer alters immunologic milieu of primary tumor (2020) (0)
- Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer (2019) (0)
- Next-generation sequencing to reveal somatic mutations that confer sensitivity to everolimus. (2015) (0)
- PD01.04 CANOPY-A: a Phase 3 Study of Canakinumab as Adjuvant Therapy in Patients with Surgically Resected NSCLC (2019) (0)
- Real-world clinical practice and outcomes in treating stage III non-small cell lung cancer: KINDLE-Asia subset (2023) (0)
- 1055P Updated results of subcutaneous (SC) anti-programmed cell death 1 (PD-1) receptor antibody PF-06801591 for locally advanced or metastatic non-small cell lung cancer (NSCLC) or urothelial carcinoma (UC) (2020) (0)
- 1275PEFFICACY OF EGFR TYROSINE KINASE INHIBITORS (EGFR TKIS) IN PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER EXCEPT BOTH EXON 19 DELETION AND EXON 21 L858R: A RETROSPECTIVE ANALYSIS IN KOREA. (2014) (0)
- Open-label, multicenter, randomized phase III trial of pemetrexed/carboplatin doublet vs pemetrexed singlet in chemotherapy-naïve elderly patients aged 70 or more with advanced non-squamous non-small cell lung cancer and good performance status. (2016) (0)
- Immune checkpoint inhibition : chemotherapy-free regimens & new PD-1 inhibitors on the horizon S 117 Early-stage lung cancer (2020) (0)
- Abstract 1787: YH29407, a novel IDO1 inhibitor, enhances the anti-tumor effects through increased tumor-reactive T cell functions in solid tumor (2021) (0)
- Clinical and Exploratory Biomarker Study of Dacomitinib in Patients with Recurrent and / or Metastatic Squamous Cell Carcinoma of Head and Neck (2015) (0)
- Abstract B11: EGFR polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI (2012) (0)
- Correction: Molecular subtypes of oropharyngeal cancer show distinct immune microenvironment related with immune checkpoint blockade response (2020) (0)
- Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer (2020) (0)
- Abstract 5194: A Mouse-Human co-clinical trial with patient-derived xenograft (PDX) models demonstrates a predictive signature for dovitinib (TKI258), an FGFR and VEGFR inhibitor,in lung squamous cell carcinomalung cancer (LSCC) (2016) (0)
- Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors. (2021) (0)
- Preclinical characterization and efficacy of 4R9, a novel immune checkpoint blockade targeting CEACAM1 for cancer therapy. (2019) (0)
- Abstract 1098: Enhanced AKT-dependent metabolic fitness and antitumor effect of T lymphocytes in lung cancer model (2019) (0)
- 510 Inhibition of STAT3 enhances the radiosensitising effect of temozolomide in malignant glioma cells in vitro and in vivo (2014) (0)
- Abstract 6780: Characterization of immunological heterogeneity in the tumor microenvironment by integrated analyses using single cell RNAseq, spatial RNAseq and multiplex IHC (2023) (0)
- Abstract 744: Transactivation of HER3 via heterodimerization with epidermal growth factor receptor (EGFR) or insulin-like growth factor 1 receptor (IGF-1R) contributes to adaptive resistance to NVP-BKM120 in non-small cell lung cancer (NSCLC) and squamous cell carcinom (2015) (0)
- 403OPACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC (2017) (0)
- Abstract 4728: FGFR1 gene amplification in small cell lung cancer (2014) (0)
- Abstract 4688: A relationship between environmental tobacco smoke (ETS) and epidermal growth factor receptor (EGFR) mutations in never smoker patients with non-small cell lung cancer (2010) (0)
- Correction: Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients with NTRK Fusion-Positive Solid Tumors. (2022) (0)
- Abstract 5107: A novel AhR inhibitor ‘DA-4505’ improved the anti-cancer efficacy of surgical and chemotherapy via synergistic anti-tumor effects of aPD-1 (2023) (0)
- Abstract P02-01: Repotrectinib in patients with NTRK fusion-positive advanced solid tumors: update from the registrational phase 2 TRIDENT-1 trial (2021) (0)
- Mutational landscapes of tongue carcinoma reveal recurrent mutations in genes of therapeutic and prognostic relevance (2015) (0)
- Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer (2022) (0)
- Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer: CANOPY-A Trial (0)
- P89.08 Real-World Impact of Plasma Cell-Free DNA Next-Generation Sequencing to Detect Actionable Genomic Alterations in Advanced NSCLC (2021) (0)
- Abstract 1148: Promising preclinical platform for evaluation of immuno-oncology drugs using Hu-PBL-NSG lung cancer models (2018) (0)
- MA 11.09 Real World Data of Rebiopsy, Mutation Status, and Its Association with Plasma Genotyping after EGFR TKI Failure in NSCLC (2017) (0)
- 3100 Phase Ib/II study of the pan-cyclin-dependent kinase (CDK) inhibitor roniciclib (BAY 1000394) in combination with chemotherapy as first-line therapy in subjects with extensive disease small cell lung cancer (ED-SCLC) (2015) (0)
- Abstract 4790: YH25448, an irreversible 3rdgeneration EGFR TKI, exhibits superior anticancer effects with potent brain BBB penetration in NSCLC (2018) (0)
- Abstract CT138: Molecular markers in a phase I dose expansion study of PF-06801591 in locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma (2020) (0)
- Abstract 1047: Advanced Lung Adenocarcinoma Cell Bank (ALACB) : A comprehensive preclinical platform (2018) (0)
- 468P Osimertinib in patients with T790M mutation positive advanced non-small cell lung cancer (NSCLC): Korean subgroup analysis from pooled phase II data (2016) (0)
- Phase I study of the CTLA-4 inhibitor MK-1308 in combination with pembrolizumab in patients with advanced solid tumors. (2018) (0)
- Targeting CDA-Directed Metabolism With 5-Formyl-2'-Deoxycytidine For ALK Inhibitor–Resistant Lung Cancer Therapy (2021) (0)
- EP-1073: The usefulness of 18F-FDG PET and PET-based considerations in locally advanced nasopharyngeal cancer (2016) (0)
- Abstract 4158: Identification of somatic mutations inEGFR/KRAS/ALK-negative lung adenocarcinoma from never smokers (2014) (0)
- Defining the immunologic phenotypes and their prognostic impacts on head and neck squamous cell cancer (HNSCC). (2016) (0)
- Whole Brain Radiation Therapy With Hippocampus-Sparing Simultaneous In-field Boost Using Helical Tomotherapy for Brain Metastases From Lung Adenocarcinoma: Early Volume Response and Dosimetric Evaluation (2013) (0)
- Abstract 3234: OCT-598, a novel EP2/EP4 dual antagonist, promotes anti-tumor immune responses in syngeneic mouse tumor models in combination with standard-of-care chemo- and immunotherapies (2023) (0)
- Abstract 4076: Finding the optimal strategy of incorporating immune checkpoint inhibitor inALK-positive non-small-cell lung cancer usingEML4-ALKtransgenic mouse model (2019) (0)
- Abstract LB544: Targeting adaptive metabolic program as a novel treatment approach for TKIs-failed ALK-positive NSCLCs (2022) (0)
- Nodal stage-oriented adjuvant chemotherapy in breast cancer (2005) (0)
- Abstract 4081: Efficacy of MERTK inhibitor in combination with pembrolizumab in lung cancer (2019) (0)
- Abstract 2755: Single-cell RNA sequencing reveals priming professional antigen-presenting macrophages and chemokine expressing T cells in tumor microenvironment by AXL inhibitor, SKI-G-801 (2021) (0)
- A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer (2014) (0)
- Abstract 2054: Cerivastatin overcomes the acquired resistance to crizotinib in EML4-ALK positive non-small cell lung cancer by controlling YAP activation (2017) (0)
- Abstract 3949: Whole exome sequencing of platinum-refractory recurrent or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN) reveals a novel cisplatin mutational signature andREV3Lmutation as a molecular predictor for dacomitinib, a p (2015) (0)
- 1348P Efficacy and safety of ceritinib 450 mg-fed vs 750 mg-fasted in Asian patients (pts) with ALK+ non-small cell lung cancer (NSCLC) in the ASCEND-8 trial (2020) (0)
- A Favorable Treatment Response of Erlotinib in Lung Adenocarcinoma with Concomitant Activating EGFR Mutation and ROS1 Rearrangement (2014) (0)
- Abstract 3346: Epigenetic downregulation of miRNA-34a and miRNA-449 induce epithelial-mesenchymal transition and acquired resistance to ceritinib (2017) (0)
- Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9. (2012) (0)
- Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors (2022) (0)
- Programmed cell death ligand 1 expression and CD8 positive lymphocytes in stage III non-small cell lung cancer after neo adjuvant concurrent chemoradiotherapy and their relation with prognosis. (2018) (0)
- Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients with Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors (2022) (0)
- Author Correction: NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma (2020) (0)
- Lack of efficacy of erlotinib in most EGFR mutated non-small cell lung cancers (NSCLCs) with acquired resistance to gefitinib (2008) (0)
- 702. Concurrent Delivery of GM-CSF and B7-1 Using an Oncolytic Adenovirus Elicits Potent Anti-Tumor Effect on the Growth Established B16-F10 Tumor Model (2005) (0)
- Predictive Biomarkers and Personalized Medicine High EGFR Gene Copy Number and Skin Rash as Predictive Markers for EGFR Tyrosine Kinase Inhibitors in Patients with Advanced Squamous Cell Lung Carcinoma (2012) (0)
- Abstract 3835: High-purity patient-derived cells: An advanced cell culture model for precision cancer medicine (2017) (0)
- Complete response of recurrent squamous cell carcinoma of the lung: dose the dose matter? (2009) (0)
- YH29407 with anti-PD-1 ameliorates anti-tumor effects via increased T cell functionality and antigen presenting machinery in the tumor microenvironment (2022) (0)
- Report from the ESMO Virtual Congress, 19th –21st September 2020 (2020) (0)
- MET exon 14 skipping mutation in non-small cell lung cancer; Diagnostic approach and clinicopathologic implications (2008) (0)
- RNF25 promotes gefitinib resistance in EGFR-mutant NSCLC cells by inducing NF-κB-mediated ERK reactivation (2018) (0)
- CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC (2019) (0)
- A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation (2022) (0)
- Phase 3 KEYNOTE‐042 Study: Pembrolizumab vs Platinum‐Based Chemotherapy as 1l Therapy for Advanced NSCLC with a PD‐L1 TPS ≥1%: PS1 (2018) (0)
- Abstract 3999: Advanced lung adenocarcinoma cell bank (ALACB) : A comprehensive preclinical platform (2019) (0)
- Abstract 5069: Comprehensive mutational analysis of epidermal growth factor receptor, EML4-ALK, and KRAS identifies four distinct disease entity in never-smoker patients with non-small cell lung cancer (2011) (0)
- A phase Ib trial of neoadjuvant chemoradiotherapy and durvalumab (MEDI4736) for potentially resectable stage III non-small cell lung cancer (NSCLC) (2019) (0)
- Real World Characteristics and Clinical Outcomes of HER2-Mutant Non–Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing (2022) (0)
- Abstract CT229: A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor, dacomitinib, in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN) (2014) (0)
- The number of residual metastatic lymph nodes following neoadjuvant chemotherapy predicts survival in patients with stage III NSCLC: P2-190 (2007) (0)
- Abstract 2476: P53 is potential predictive biomarker for combination therapy of epidermal growth factor receptor (EGFR) and MET inhibitors in non-small cell lung cancer (NSCLC) with wild-type EGFR (2012) (0)
- MO01.22 Canakinumab as Adjuvant Therapy in Patients with Completely Resected Non-Small Cell Lung Cancer (NSCLC): CANOPY-A Trial (2021) (0)
- A pilot study of transarterial injection of 166Holmium-Chitosan complex in the treatment of single and small hepatocellular carcinoma (HCC) (2005) (0)
- Abstract 2166: Analysis of ctDNA next generation sequencing (NGS) for predicting response to amivantamab and lazertinib among patients with EGFR-mutant NSCLC after progression on osimertinib and platinum-based chemotherapy (CHRYSALIS-2 Cohort A) (2023) (0)
- Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma (2013) (0)
- Impact of second hand smoke(SHS) exposure on the likelihood of mutations in epidermal growth factor receptor(EGFR) gene in patients with non-small cell lung cancer(NSCLC) who had never smoked: P1-041 (2007) (0)
- Efficacy and Safety of Ceritinib 450 mg/day with Food and 750 mg/day in Fasted State in Treatment-Naïve Patients with ALK+ Non–Small Cell Lung Cancer: Results from the ASCEND-8 Asian Subgroup Analysis (2022) (0)
- Abstract 677: EML4-ALK fusion gene expressing transgenic mouse for lung cancer model (2016) (0)
- Abstract 4006: TRX-221, a novel 4th-generation EGFR inhibitor for overcoming C797S mutation-mediated acquired resistance in NSCLC (2023) (0)
- The prognostic value of comprehensive geriatric assessment on the management of older patients with small cell lung cancer (2022) (0)
- Abstract CT287: CANOPY-A: A phase III, multicenter, randomized trial evaluating canakinumab versus placebo as adjuvant therapy in patients with completely resected non-small cell lung cancer (NSCLC) (2020) (0)
- 364 KRAS mutations in patients with nonsquamous non–small-cell lung cancer: prevalence and relationship with PD-L1 expression, tumor mutation burden and smoking status (2021) (0)
- Phase II study of afatinib in recurrent and/or metastatic esophageal squamous cell carcinoma (R/M ESCC) (KCSG HN14-18). (2017) (0)
- Lazertinib in pretreated EGFR T790M-mutated advanced non-small cell lung cancer: A real-world multicenter study. (2023) (0)
- A multicenter phase II study of everolimus in patients with progressive unresectable adenoid cystic carcinoma (2014) (0)
- 475 Anti-TIGIT antibody tiragolumab leverages myeloid cells and regulatory T cells to improve PD-L1 checkpoint blockade (2022) (0)
- 718 Preliminary results of GII-101-P101 (Keynote-B59): GI-101 (CD80-IgG4 Fc-IL2v) as a single agent and in combination with pembrolizumab in patients with advanced and/or metastatic solid tumors (2022) (0)
- Tepotinib in patients (pts) with NSCLC with MET exon 14 (METex14) skipping: Health-related quality of life (HRQoL). (2020) (0)
- A case of toxoplasmosis mimicking systemic recurrence in a patient treated with breast cancer (2006) (0)
- P2.03a-038 Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo-Naïve Elderly Non-SQCC NSCLC Patients Aged ≥ 70: Topic: Clinical Trials (2017) (0)
- The Frequency and Impact of Fibroblast Growth Factor Receptor 1 Amplification and p16 Protein Expression on Clinical Outcomes in Resected Head and Neck Squamous Cell Carcinoma (2008) (0)
- Mobilized circulating endothelial progenitor cells after the first cycle of chemotherapy with prophylactic G-CSF can be used as a predictive biomarker and patient selection marker for anti-angiogenesis combination treatment (2007) (0)
- Abstract P224: Update from the Phase 2 registrational trial of repotrectinib in TKI-pretreated patients with ROS1+ advanced non-small cell lung cancer and with NTRK+ advanced solid tumors (TRIDENT-1) (2021) (0)
- Advances in the management of non-small-cell lung cancer harbouring EGFR exon 20 insertion mutations (2023) (0)
- AcceleRET Lung: A phase 3 study of first-line pralsetinib in patients with RET fusion–positive advanced/metastatic NSCLC. (2022) (0)
- Abstract 4029: JIN-A04, highly effective tyrosine kinase inhibitor targeting HER2 exon 20 insertion mutations in NSCLC (2023) (0)
- A randomized; phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (vol 8; pg 15943; 2017) (2017) (0)
- Abstract 4946: Comprehensive molecular profiling reveals distinct immunemicroenvironment subtypes of oropharyngeal cancers (2019) (0)
- A study to identify incidence of ROS1 rearrangement in lung adenocarcinoma, cholangiocarcinoma and glioblastoma multiforme. (2015) (0)
- 8502 ORAL Phase II Study of RAD001 Monotherapy in Patients With Unresectable Adenoid Cystic Carcinoma (2011) (0)
- O8-4 KEYNOTE-042: 5-year update of first-line pembrolizumab in Asian patients with locally advanced/metastatic PD-L1-positive NSCLC (2022) (0)
- A prospective phase II trial of a S-1/cisplatin-based chemoradiotherapy for locoregionally advanced esophageal cancer. (2012) (0)
- Abstract CT024: Acquired resistance in patients with EGFRm NSCLC following treatment with osimertinib plus savolitinib in the Ph1b TATTON study Parts B and D (2021) (0)
- 1928P Pathologic assessment following neoadjuvant immunotherapy or chemotherapy demonstrates similar patterns in non-small cell lung cancer (NSCLC) (2018) (0)
- Abstract 3071: Repotrectinib demonstrates promising activities inROS1wild-type and solvent-front mutant lung cancer patients-derived preclinical models (2019) (0)
- Abstract 5189: Neoadjuvant and adjuvant anti-PD-1 based combination immunotherapy with a novel AXL inhibitor, SKI-G-801 in syngeneic tumor model: A combined analysis of immune profiling (2020) (0)
- PP223 Single-cell RNA sequencing in metastatic lung cancer uncovers the efficacy of PD-1/PD-L1 inhibitors on immune cell population (2022) (0)
- Artificial intelligence-based non-small cell lung cancer transcriptome RNA-sequence analysis technology selection guide (2023) (0)
- P1.01-01 ROS1-Positive Non-Small Cell Lung Cancer: Real-World Data in Korea (2018) (0)
- Abstract 741: Anti-tumor activity and acquired resistance mechanism of dovitinib in RET-rearranged lung adenocarcinoma (2015) (0)
- Abstract CT255: Canakinumab as adjuvant therapy in patients with completely resected non-small cell lung cancer: CANOPY-A trial (2021) (0)
- A real-world study of second or later-line osimertinib in patients with EGFR T790M-positive NSCLC: the final ASTRIS data. (2023) (0)
- ASTRIS global real world study of osimertinib in patients (pts) with EGFR T790M non-small cell lung cancer (NSCLC): Subpopulation analyses. (2018) (0)
- Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01) (2017) (0)
- Abstract 1106: BRAF and EGFR fusion as a novel mechanism of resistance mechanism to Lazertinib, 3rd- generation EGFR-TKI, in EGFR-mutant NSCLC (2021) (0)
- Peripheral natural killer cells and myeloid-derived suppressor cells correlate with anti-PD-1 responses in non-small cell lung cancer (2020) (0)
- Abstract 5935: Phenotype profiling of tumor microenvironment in EGFR mutant lung adenocarcinoma with multi-omics data (2023) (0)
- FP14.14 Post Hoc Analyses from an Open Label, Multi-Centre, ASTRIS Trial of Efficacy of Osimertinib for CNS Metastases with T790M-Positive Advanced NSCLC (2021) (0)
- P3.01-005 ASTRIS: A Real World Study of Osimertinib Treatment in Patients with EGFR T790M Positive Advanced NSCLC; Interim Analysis (2017) (0)
- P-34 The randomized, double-blind, placebo-controlled phase 3 trial KEYNOTE-975: Pembrolizumab vs placebo in patients with esophageal carcinoma receiving concurrent definitive chemoradiotherapy (2020) (0)
- A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor dacomitinib in patients with recurrent and/or metastatic squamous cell carcinoma of esophagus. (2014) (0)
- A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naïve, cisplatin-ineligible urothelial cancer. (2023) (0)
- 140. Enhanced Cell Killing Effect of E1 Modified Adenoviruses Expressing HSV-TK Suicide Gene (2006) (0)
- Abstract 2104: ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor in head and neck squamous cell carcinoma (2016) (0)
- Comprehensive analysis of mutation and expression based pathways in head and neck squamous cell carcinoma. (2018) (0)
- 1358P Phase I dose-escalation study to evaluate safety and clinical activity of c-MET inhibitor ABN401 in patients with advanced solid tumor (2021) (0)
- 422PA real world treatment study of osimertinib: ASTRIS study Korean subgroup analysis (2017) (0)
- Phase 3 Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib vs. Concurrent Chemoradiation Therapy in Patients With Newly Diagnosed Limited-Stage Small-Cell Lung Cancer: KEYLYNK-013. (2021) (0)
- Abstract 1471: Incorporation of SKI-G-801, novel AXL inhibitor, with anti-PD-1 inhibitor plus chemotherapy improved anti-tumor activity and survival outcome via enhancing anti-tumor T cell immunity (2021) (0)
- Phase II study of nivolumab in patients with advanced non-small cell lung cancer (NSCLC) in Korea. (2017) (0)
- Abstract 2855: Identification of optimal treatment sequence and acquired resistance mechanisms of ALK inhibitors using EML4-ALK transgenic mouse model (2018) (0)
- Murine Model Expressing Interleukin-12 and B 7-1 in an Immunocompetent Enhanced Antitumor Effect of Oncolytic Adenovirus (2006) (0)
- Copy Number Abnormalities and Gene Fusions in Lung Cancer: Present and Developing Technologies (2018) (0)
- Abstract CT561: KeyVibe-003: Randomized, double-blind, phase 3 study of first-line pembrolizumab with and without vibostolimab (anti-TIGIT) in patients with PD-L1-positive metastatic NSCLC (2022) (0)
- Abstract CT127: Tumor response and MET-detection methods exploratory biomarker analysis of Part B of the Ph 1b TATTON study (2021) (0)
- A real-world study of osimertinib: ASTRIS 2nd DCO Korean subgroup analysis. (2018) (0)
- Updated results confirm efficacy and safety of entrectinib in patients with NTRK fusion-positive NSCLC (2022) (0)
- MO4-1 Management of infusion-related reactions in patients receiving amivantamab in the CHRYSALIS study (2022) (0)
- ES30.04 Monoclonal Antibodies Targeting the ErbB Receptors (2021) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Byoung Chul Cho?
Byoung Chul Cho is affiliated with the following schools:
